title: Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo.
abstract: Childhood Acute Lymphoblastic Leukemia (ALL) represents approximately 40% of pediatric cancers, but molecular mechanisms involved in the therapeutic resistance of ALL are still unclear. The disregulation of cell cycle could be a mechanism of progression of leukemic blasts and glucocorticoids (GCs), the main pharmacological agent in the treatment of ALL, could affect cell cycle distribution. In our study we have evaluated cell cycle distribution and the expression of several molecules involved in cell cycle regulation in blasts collected from 32 patients with ALL before and 48 h after treatment with GCs. A significant increase of the percentage of ALL blasts in G(0)/G(1) phase was recorded after treatment with GCs in 22 (69%) out of 32 patients and 18 of these patients were also good responders to GC therapy. In these patients an increase of the expression of at least one of the 4 evaluated CDKIs (p15, p16, p21 and p27) was found in 29 out of 32 patients (90.6%) without any change in CDK2 and 4 expression. All patients expressed detectable levels of Rb-1 phosphorylation at the diagnosis. Twenty (63%) patients showed a decrease, while two patients showed an increase of p110 Rb-1 phosphorylation and no changes were detected in the remaining 10 patients after GC therapy. The univariate analysis showed that the reduction of pRb-1 phosphorylation was significantly higher in B-cell lineage patients and in good responders. In conclusion, this is the first report that evaluate the Rb-1 function as predictor of response in childhood ALL and our data suggest that its hypophosphorylation and, consequently, reduced activity correlates with a statistical significance with the responsiveness to GC therapy. These results suggest that Rb-1 can be a useful molecular target for the therapy of this subset of patients.
authors.affiliation: Pediatric Oncology Service, Pediatric Department, II University of Naples, Napoli, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Addeo
authors.forename: Fiorina
authors.initials: F
authors.lastname: Casale
authors.forename: Michele
authors.initials: M
authors.lastname: Caraglia
authors.forename: Velia
authors.initials: V
authors.lastname: D'Angelo
authors.forename: Stefania
authors.initials: S
authors.lastname: Crisci
authors.forename: Alberto
authors.initials: A
authors.lastname: Abbruzzese
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Di Tullio
authors.forename: Paolo
authors.initials: P
authors.lastname: Indolfi
mesh_terms: D001752:Blast Crisis; D018797:Cell Cycle Proteins / Q000378:metabolism; D002648:Child; D016213:Cyclins / Q000378:metabolism; D005260:Female; D016193:G1 Phase / Q000187:drug effects*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010766:Phosphorylation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D011241:Prednisone / Q000627:therapeutic use*; D016160:Retinoblastoma Protein / Q000378:metabolism*
chemical_list: D018797:Cell Cycle Proteins; D016213:Cyclins; D005938:Glucocorticoids; D016160:Retinoblastoma Protein; D011241:Prednisone